iTeos Therapeutics

Foundation date

01/08/2011

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients . We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies.

Upcoming events

Latest news

  • Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

    14 hours ago

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    Thursday September 29th 2022

  • FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome

    Tuesday September 27th 2022